COVID-19. Covid-19
Conditions
Interventions
Intervention 1: Intervention group: Interferon Beta 1a nasal spray 1 puff in each nostril every 6 hours, for 14 days (In addition to routine treatment according to the latest national guideline for
Sponsors
Bagheiat-allah University of Medical Sciences
Cinnagen company
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age: equal or more than 18 years; The patient have written consciously and freely consent to participate in the study; The patient's clinical symptoms (dry cough, shortness of breath, fever) confirm COVID-19. Confirmed diagnosis of COVID-19, with either lung CT-Scan result, which is typical for COVID-19 pulmonary involvement,or RT-PCR confirmation. Less than 7 days have passed since the onset of symptoms.
Exclusion criteria
Exclusion criteria: History of allergy to this nasal spray ingredients; Hypersensitivity reaction while taking this nasal spray; The patient is in another clinical trial at the same time; The patient needs to receive medical care from the intensive care unit; Pregnancy; Lactation. Chronic kidney disease, stage 3 to 5; Receiving ACEI/ARB group;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms (dry cough). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Clinical symptoms (respiratory distress). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Pulse-oxymetery device.;Clinical symptoms (fever). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 7 from the initiation, is recorded. Method of measurement: Thermometer. | — |
Secondary
| Measure | Time frame |
|---|---|
| Lab. tests changes. Timepoint: Daily monitoring, but the before the intervention initiation (baseline) and day 7 results will recorded on designed checklist. Method of measurement: Blood sample, laboratory analysis.;Side effects. Timepoint: Daily monitoring, but the before the intervention initiation (baseline) and day 7 results will recorded on designed checklist. Method of measurement: Physical examination.;Mortality. Timepoint: Day 14 from the initiation. Method of measurement: Clinical assessment. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyed Hasan Saadat
Bagheiat-allah University of Medical Sciences
Outcome results
None listed